 Connection
Uwe Christians to Everolimus
This is a "connection" page, showing publications Uwe Christians has written about Everolimus.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.096 |
|
|
|
-
Schniedewind B, Meyer EJ, Christians U. Long-Term Performance of Laboratory-Developed Liquid Chromatography-Tandem Mass Spectrometry Tests and a Food and Drug Administration-Approved Immunoassay for the Therapeutic Drug Monitoring of Everolimus. Ther Drug Monit. 2020 06; 42(3):421-426.
Score: 0.668
-
Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015 Jul; 14(7):1055-70.
Score: 0.469
-
Lesche D, Sigurdardottir V, Leichtle AB, Nakas CT, Christians U, Englberger L, Fiedler M, Largiad?r CR, Mohacsi P, Sistonen J. Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement. Metabolomics. 2017 11 25; 14(1):3.
Score: 0.140
-
Schniedewind B, Niederlechner S, Galinkin JL, Johnson-Davis KL, Christians U, Meyer EJ. Long-term cross-validation of everolimus therapeutic drug monitoring assays: the Zortracker study. Ther Drug Monit. 2015 Jun; 37(3):296-303.
Score: 0.118
-
Strom T, Haschke M, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit. 2007 Dec; 29(6):743-9.
Score: 0.070
-
Strom T, Haschke M, Zhang YL, Bendrick-Peart J, Boyd J, Roberts M, Arabshahi L, Marbach P, Christians U. Identification of everolimus metabolite patterns in trough blood samples of kidney transplant patients. Ther Drug Monit. 2007 Oct; 29(5):592-9.
Score: 0.069
-
Boernsen KO, Egge-Jacobsen W, Inverardi B, Strom T, Streit F, Schiebel HM, Benet LZ, Christians U. Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom. 2007 Jun; 42(6):793-802.
Score: 0.068
-
Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit. 2005 Dec; 27(6):733-7.
Score: 0.061
-
Christians U, Gottschalk S, Miljus J, Hainz C, Benet LZ, Leibfritz D, Serkova N. Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol. 2004 Oct; 143(3):388-96.
Score: 0.056
-
Serkova N, Jacobsen W, Niemann CU, Litt L, Benet LZ, Leibfritz D, Christians U. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol. 2001 Jul; 133(6):875-85.
Score: 0.045
-
Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc. 2001 Feb-Mar; 33(1-2):514-5.
Score: 0.044
-
Serkova N, Hausen B, Berry GJ, Jacobsen W, Benet LZ, Morris RE, Christians U. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther. 2000 Jul; 294(1):323-32.
Score: 0.042
-
Serkova N, Litt L, Leibfritz D, Hausen B, Morris RE, James TL, Benet LZ, Christians U. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates. Br J Pharmacol. 2000 Feb; 129(3):485-92.
Score: 0.041
-
Segarra I, Brazelton TR, Guterman N, Hausen B, Jacobsen W, Morris RE, Benet LZ, Christians U. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. J Chromatogr B Biomed Sci Appl. 1998 Dec 11; 720(1-2):179-87.
Score: 0.038
-
Shihab F, Christians U, Smith L, Wellen JR, Kaplan B. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014 Jun; 31(1):22-32.
Score: 0.027
-
Bohra R, Sch?ning W, Klawitter J, Brunner N, Schmitz V, Shokati T, Lawrence R, Arbelaez MF, Schniedewind B, Christians U, Klawitter J. Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. PLoS One. 2012; 7(10):e48063.
Score: 0.025
-
Gottschalk S, Cummins CL, Leibfritz D, Christians U, Benet LZ, Serkova NJ. Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology. 2011 Jan; 32(1):50-7.
Score: 0.022
-
Klawitter J, Gottschalk S, Hainz C, Leibfritz D, Christians U, Serkova NJ. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. 2010 Mar 15; 23(3):608-19.
Score: 0.021
-
Kirchner G, Mueller L, Winkler M, Loss M, Roechte F, Deters M, Christians U, Kaever V, Klempnauer J, Sewing K, Manns M. Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients. Transplant Proc. 2002 Sep; 34(6):2233-4.
Score: 0.012
-
Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001 Jun 07; 44(12):2027-34.
Score: 0.011
-
Hausen B, Boeke K, Berry GJ, Christians U, Sch?ler W, Morris RE. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD. Ann Thorac Surg. 2000 Mar; 69(3):904-9.
Score: 0.010
-
Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation. 2000 Feb 27; 69(4):488-96.
Score: 0.010
-
Hausen B, Ikonen T, Briffa N, Berry GJ, Christians U, Robbins RC, Hook L, Serkova N, Benet LZ, Schuler W, Morris RE. Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. Transplantation. 2000 Jan 15; 69(1):76-86.
Score: 0.010
-
Hausen B, Boeke K, Berry GJ, Segarra I, Benet LZ, Christians U, Morris RE. Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. Transplantation. 1999 Apr 15; 67(7):956-62.
Score: 0.010
-
Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant. 1999 Feb; 18(2):150-9.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|